Novacyt

Equities

ALNOV

FR0010397232

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:23:03 2024-05-21 am EDT			Pre-market 02:21:05 am
0.734 ^EUR	+3.38%		0.723	-1.50%

May. 01	Novacyt Says UK Court Dismissed Government's Summary Judgment Application	MT
May. 01	Novacyt notes court dismissal of UK DHSC summary judgment application	AN

Novacyt S.A. Announces Revenue Guidance for 2018

December 24, 2018 at 02:00 am EST

Novacyt S.A. announced that the company estimates revenue from continuing operations, which will include the Primer design and Lab21 business units, of €13.7 million to €14.4 million, which compares to the market consensus of €15.85 million.

Latest news about Novacyt

Novacyt Says UK Court Dismissed Government's Summary Judgment Application	May. 01	MT
Novacyt notes court dismissal of UK DHSC summary judgment application	May. 01	AN
Novacyt: confident ahead of DHSC trial	Apr. 19	CF
Novacyt expects court to dismiss application by UK DHSC	Apr. 19	AN
Novacyt expects court to dismiss application by UK DHSC	Apr. 19	AN
AIM WINNERS & LOSERS: Ethernity loss narrows; Fonix staff sell shares	Apr. 19	AN
Yourgene CEO to become head of Novacyt after acquisition	Apr. 11	AN
Novacyt: changes to the Board of Directors	Apr. 11	CF
Novacyt's New CEO to Start May	Apr. 11	MT
Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024	Apr. 11	CI
Novacyt S.A. Announces CEO Changes, Effective on May 1, 2024	Apr. 11	CI
FTSE 100 Closes Up 0.9%, Lifted by BP	Feb. 06	DJ
Novacyt says talks to sell Taiwan laboratory are terminated	Feb. 06	AN
Novacyt: Taiwanese laboratory retained	Feb. 06	CF
Novacyt's Discussions for Taiwanese Unit Sale Fall Through	Feb. 06	MT
Treatt revenue falls; Secure Trust profit picks up	Jan. 25	AN
Novacyt appoints new CFO	Jan. 02	CF
Novacyt promotes Finance Director Steve Gibson to CFO	Jan. 02	AN
Novacyt Names Finance Director as New CFO	Jan. 02	MT
Novacyt notes delay of divestment as awaits approvals	Dec. 21	AN
FTSE 100 Closes Down 0.3% Dragged by Oil Stocks	Dec. 21	DJ
Novacyt: sale to Taiwan not finalized before 2024	Dec. 21	CF
Novacyt Delays Closure of Yourgene Health Taiwan's Sale	Dec. 21	MT
Actual Experience appoints administrators	Nov. 07	AN
Novacyt: IVDR accreditation for Yourgene DPYD test	Nov. 07	CF

Chart Novacyt

Duration

Period

More charts

Company Profile

Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors: - development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular screening kits (Primerdesign): for laboratories.

Sector

Biotechnology & Medical Research

Calendar

2024-05-30 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Medical Devices

	1st Jan change	Capi.
NOVACYT	+2.95%	56.25M
MIMEDX GROUP, INC.	-9.35%	1.17B
NIBEC CO., LTD.	-21.62%	127M
COLLPLANT BIOTECHNOLOGIES LTD.	-4.54%	69.86M
KIM FOREST ENTERPRISE CO., LTD.	+3.52%	59.36M

Bio Medical Devices